无干扰素抗HCV方案的研究进展 |
| |
引用本文: | 李强,黄玉仙,陈良.无干扰素抗HCV方案的研究进展[J].临床肝胆病杂志,2016(1):169-173. |
| |
作者姓名: | 李强 黄玉仙 陈良 |
| |
作者单位: | 复旦大学附属公共卫生临床中心 肝炎一科,上海,201508 |
| |
基金项目: | 上海市科委“科技创新行动计划”医学与农业领域重点项目,上海市卫生局临床医学应用研究项目 |
| |
摘 要: | 当前,全球约有1.5亿慢性HCV感染者,其中20%会进展为肝硬化并最终死于终末期肝病和肝癌。干扰素(IFN)长期作为慢性丙型肝炎治疗的基石,在维持持续病毒学应答以及阻止病情进展方面有重要作用,但其疗效有限、不良反应多。近年来,直接抗病毒药物(DAAs)呈现出良好的疗效,在DAAs的基础上,介绍了无IFN抗HCV方案的最新研究进展,认为随着DAAs的出现,无IFN抗HCV方案发展迅速,前景较好。
|
关 键 词: | 肝炎 丙型 慢性 抗病毒药 蛋白酶抑制药 综述 |
Research progress in anti-HCV therapeutic regimens without interferon |
| |
Abstract: | There are about 150 million people around the world with chronic hepatitis C virus (HCV)infection currently,of whom 20%will ultimately progress to cirrhosis and eventually die of end-stage liver disease and hepatocellular carcinoma.Interferon (IFN)has long been recognized as the cornerstone of the treatment of chronic hepatitis C because of its role in sustained virologic response and prevention of disease progression.However,it has limited efficacy and multiple adverse effects.In recent years,direct-acting antiviral agents (DAAs) have shown good efficacy.This review summarizes the recent advances in IFN-free anti-HCV therapeutic regimens based on DAAs.We believe that,with the emergence of DAAs,IFN-free therapies will develop rapidly and display better prospects. |
| |
Keywords: | hepatitis C chronic antiviral agents protease inhibitors review |
本文献已被 CNKI 万方数据 等数据库收录! |
|